In Itapira, a town in São Paulo with a population of 72,000, a hospital has become the center for collecting placenta donations, which are essential for producing polilaminin. This substance is undergoing clinical testing with authorization from Brazil's ANVISA for the treatment of individuals suffering from acute spinal cord injuries. The hospital averages 40 births per month and began collaborating with a private laboratory in April 2025 to facilitate this research.

Polilaminin is a laboratory-created compound derived from laminin, a protein naturally produced in the human body, particularly important during embryonic development for tissue organization and cellular growth. So far, 140 mothers have participated in this research project, providing their placentas after childbirth. The hospital's nursing team plays a crucial role by warmly welcoming expectant mothers, engaging them in conversation about the project, and allowing them to decide whether they wish to donate their placentas.

The implications of this research are significant as it represents a step forward in regenerative medicine, particularly concerning spinal cord injury treatments, which often have limited therapeutic options available. If successful, the research could open new avenues for improving the quality of life for patients with such injuries, potentially leading to broader applications in tissue repair and healing processes across various medical fields.